IL6 and COVID-19: Although we could not find an association of serum IL-6 with the clinical course of our patients and although experimental data indicate potentially harmful effects of IL-6R blockade in experimental lung injury there have been occasional reports of therapeutic success with tocilizumab in COVID-19 25,39.